Trials / Unknown
UnknownNCT02311010
Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
Influence of Recipient Cytochrome P450 3A5 Polymorphism on the Metabolism of Prolonged Release Tacrolimus Administered de Novo After Renal Transplantation
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Université Catholique de Louvain · Academic / Other
- Sex
- All
- Age
- 15 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of the genetic Cyp 450 3A5 polymorphism of the recipient. The study of the tacrolimus through level (ng/ml) determines if the therapeutic level is reached.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Advagraf | daily dose adapted according to Cyp 3A5 polymorphism |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2014-10-01
- Completion
- 2015-01-01
- First posted
- 2014-12-08
- Last updated
- 2014-12-08
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02311010. Inclusion in this directory is not an endorsement.